AAD minoxidil
This article was originally published in The Rose Sheet
Executive Summary
Patients who suffer from allergic contact dermatitis due to treatment with topical minoxidil solution "should be advised to undergo patch testing to determine the causative allergen," researchers report in the February Journal of the American Academy of Dermatology. Edward Friedman, et al., New York University School of Medicine, suggest these patients could be sensitive to an agent in the solution other than minoxidil, such as propylene glycol, in which case "they should be given the option of formulations compounded with alternative solvents." Friedman et al. patch tested 11 individuals with alopecia; nine showed a positive allergic reaction to propylene glycol, while only four reacted to minoxidil...
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.